

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana,

India

CIN: L85195TG1984PLC004507

Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

January 09, 2024

To, BSE Limited, P J Towers, Dalal Street, Mumbai -400001, India

Kind Attn.: Mr. Harshad Naik, Deputy Manager, Listing Compliance

Dear Sir/ Madam,

Sub: <u>Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements)</u>
Regulations, 2015 – clarification on reported news article published in electronic media, <a href="https://www.business-standard.com">https://www.business-standard.com</a> on January 7, 2024

This is with reference to your e-mail dated January 8, 2024 and in relation to a news article which appeared in <a href="https://www.business-standard.com">https://www.business-standard.com</a> on January 7, 2024, with the heading "Dr Reddy's recalls 8,000 bottles of generic drug in US over packaging error".

In this connection, we would like to inform that on December 15, 2023, Dr. Reddy's Laboratories Inc., wholly owned subsidiary of Dr. Reddy's Laboratories Limited, initiated a limited voluntary recall of one (1) specific batch of Tacrolimus capsules, 1 mg, from the U.S. market as a precautionary measure. The batch contains distributed quantity of 8,280 bottles of 100 capsules each. The single-batch recall was voluntarily initiated by the Company due to a product complaint for one foreign capsule in a single bottle (one 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules). Tacrolimus capsules are immunosuppressants. This recall will have negligible impact on patient safety. The Company continues to supply the product to the U.S. market.

Please note that the above mentioned event/information was not considered as material requiring disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'). We further inform that there is no material impact of the above reported news item published in Business Standard on the Company.

In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations.

This is for your information and record.

Thanking you.

Yours faithfully, For **Dr. Reddy's Laboratories Limited** 

## K Randhir Singh

Company Secretary, Compliance Officer and Head-CSR